Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/11930Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Andrews, Miles C | - |
| dc.contributor.author | Behren, Andreas | - |
| dc.contributor.author | Chionh, Fiona | - |
| dc.contributor.author | Mariadason, John M | - |
| dc.contributor.author | Vella, Laura J | - |
| dc.contributor.author | Do, Hongdo | - |
| dc.contributor.author | Dobrovic, Alexander | - |
| dc.contributor.author | Tebbutt, Niall C | - |
| dc.contributor.author | Cebon, Jonathan S | - |
| dc.date.accessioned | 2015-05-16T01:33:50Z | |
| dc.date.available | 2015-05-16T01:33:50Z | |
| dc.date.issued | 2013-11-04 | - |
| dc.identifier.citation | Journal of Clinical Oncology 2013; 31(35): e448-51 | en |
| dc.identifier.other | PUBMED | en |
| dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/11930 | en |
| dc.language.iso | en | en |
| dc.subject.other | Cell Proliferation.drug effects | en |
| dc.subject.other | Colonic Neoplasms.drug therapy.genetics.pathology | en |
| dc.subject.other | Humans | en |
| dc.subject.other | Imidazoles.therapeutic use | en |
| dc.subject.other | MAP Kinase Kinase 1.antagonists & inhibitors.metabolism | en |
| dc.subject.other | MAP Kinase Kinase 2.antagonists & inhibitors.metabolism | en |
| dc.subject.other | Male | en |
| dc.subject.other | Middle Aged | en |
| dc.subject.other | Mutation | en |
| dc.subject.other | Oximes.therapeutic use | en |
| dc.subject.other | Protein Kinase Inhibitors.therapeutic use | en |
| dc.subject.other | Proto-Oncogene Proteins.genetics | en |
| dc.subject.other | Proto-Oncogene Proteins B-raf.antagonists & inhibitors.metabolism | en |
| dc.subject.other | Pyridones.therapeutic use | en |
| dc.subject.other | Pyrimidinones.therapeutic use | en |
| dc.subject.other | Treatment Outcome | en |
| dc.subject.other | ras Proteins.genetics | en |
| dc.title | BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition. | en |
| dc.type | Journal Article | en |
| dc.identifier.journaltitle | Journal of Clinical Oncology | en |
| dc.identifier.affiliation | Joint Ludwig-Austin Oncology Unit, Austin Health, Victoria, Australia | en |
| dc.identifier.doi | 10.1200/JCO.2013.50.4118 | en |
| dc.description.pages | e448-51 | en |
| dc.relation.url | https://pubmed.ncbi.nlm.nih.gov/24190114 | en |
| dc.type.content | Text | en |
| dc.type.austin | Journal Article | en |
| local.name.researcher | Cebon, Jonathan S | |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| item.openairetype | Journal Article | - |
| item.grantfulltext | none | - |
| item.cerifentitytype | Publications | - |
| item.fulltext | No Fulltext | - |
| item.languageiso639-1 | en | - |
| crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
| crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
| crisitem.author.dept | Surgery (University of Melbourne) | - |
| crisitem.author.dept | Medical Oncology | - |
| crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
| crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
| Appears in Collections: | Journal articles | |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.